tiprankstipranks

Poseida Therapeutics says FDA grants RMAT designation to P-BCMA-ALLO1

Poseida Therapeutics announced that the U.S. FDA granted Regenerative Medicine Advanced Therapy designation to P-BCMA-ALLO1, an investigational stem cell memory T cell-based allogeneic CAR-T cell therapy in Phase 1/1b clinical development for the treatment of patients with relapsed/refractory multiple myeloma.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue